4SC - Resminostat and RESMAIN Study Update - 4SC AG
4SC AG announced the Data Safety Monitoring Board recommends continuing the RESMAIN study without changes. This study evaluates resminostat for advanced-stage cutaneous T-cell lymphoma maintenance treatment. Recruitment is closed, with unblinding and top-line data expected in Q1 2023. Resminostat aims to prolong progression-free survival and improve quality of life.
Reference News
4SC - Resminostat and RESMAIN Study Update - 4SC AG
4SC AG announced the Data Safety Monitoring Board recommends continuing the RESMAIN study without changes. This study evaluates resminostat for advanced-stage cutaneous T-cell lymphoma maintenance treatment. Recruitment is closed, with unblinding and top-line data expected in Q1 2023. Resminostat aims to prolong progression-free survival and improve quality of life.